Biologic therapies have changed the outcome of both adult and pediatric patients with Inflammatory Bowel Disease (IBD). In September 2013, the first biosimilar of infliximab was introduced into the pharmaceutical market. In 2015, a first position paper on the use of biosimilars in pediatric IBD was published by the ESPGHAN IBD Porto group. Since then, more data have accumulated for both adults and children demonstrating biosimilars are an effective and safe alternative to the originator. In this updated position statement, we summarize current evidence and provide joint consensus statements regarding the recommended practice of biosimilar use in children with IBD.

Department of Neuroscience Psychology Pharmacology and Child's Health University of Florence Meyer Hospital Florence

Department of Paediatric Gastroenterology and Nutrition Jagiellonian University Medical College Krakow Poland

Department of Paediatric Gastroenterology University Medical Center Utrecht Wilhelmina Children's Hospital Utrecht The Netherlands

Department of Paediatrics and Adolescence Medicine GPGE Educational Center of Paediatric Gastroenterology Medical University of Graz Graz Austria

Department of Paediatrics Southampton Children's Hospital Tremona Road Southampton United Kingdom

Department of Paediatrics University Hospital Motol Prague Czech Republic

Department of Woman Child and General and Specialistic Surgery University of Campania Luigi Vanvitelli Naples

Erasmus MC Sophia Children's Hospital Rotterdam The Netherlands

Harvard Medical School MassGeneral Hospital for Children Boston MA

Hepatology Gasroenterology and Nutrition Unit Bambino Gesù Children Hospital Rome Italy

Hospital Pharmacy Erasmus MC Rotterdam The Netherlands

KU Leuven Department of Pharmaceutical and Pharmacological Sciences Leuven Belgium

Pediatric Gastroenterology and Cystic Fibrosis Unit University of Messina Messina Italy

Pediatric Gastroenterology Department of Paediatrics Hospital Sao João Porto Portugal

Pediatric Institute of the University of Debrecen Debrecen Hungary

Schneider Children's Hospital Petach Tikva affiliated to the Sackler Faculty of Medicine Tel Aviv University Israel

The Royal Hospital for Children Glasgow

References provided by Crossref.org

Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation